Press Releases

09 January 2024




Agreement with Alcyon Italia for the distribution of BIOCERA-VET® product line in Italy




04 January 2024




TheraVet reports significant success of its the last educational webinar on canine osteosarcoma co-organized with Veterinary Instrumentation (UK)




6 December 2023




TheraVet reports further achievements on its Osteosarcoma Program




23 November 2023 





Launch of BIOCERA-VET® Canine Osteosarcoma Study conducted by the prestigious University of Florida



08 November 2023




Significant Sales Progression for BIOCERA-VET® in Q3 2023




25 October 2023




TheraVet announces the appointment of a Chief Financial Officer to reinforce its global financing and cost control strategy




18 October 2023 




Increasingly successful attendance in major ortho EU & US conferences and North America launch of BIOCERA-VET COMBO-CLEAN




11 October 2023



BIOCERA-VET in Horse Bone Cysts Highlighted at an International Equine Conference in the USA




27 September 2023




Patient recruitment phase successfully completed in BIOCERA-VET fracture revision surgery study in toy dogs



11 July 2023





TheraVet provides an update on its 2023 half-year development and portfolio strategy





15 June 2023 




TheraVet announces 300% increase in participating Centers in the Osteosarcoma Program since its initiation 6 months ago




31 May 2023 




TheraVet announces the commercial launch of a local and sustained antibiotic releasing bone substitute




04 May 2023




TheraVet continues the assessment of BIOCERA-VET in a new clinical program




06 April 2023




TheraVet launches its Osteosarcoma Reference Centers program




21 February 2023 




TheraVet signs an international distribution agreement for BIOCERA-VET® covering 24 countries




15 January 2023




TheraVet announces the start of the assessment of BIOCERA-VET® in horse bone cyst




12 December 2022




TheraVet optimizes its commercial strategy in France with a new distribution agreement for its BIOCERA-VET® range


7 December 2022



BIOCERA-VET® nominated for the Veterinary Innovation Award (AFVAC 2022)







26 September 2022




TheraVet announces an exclusive distribution agreement for BIOCERA-VET® in the USA




19 September 2022




TheraVet announces its participation in the 2022 ESVOT Congress with 3 scientific communications




09 September 2022



TheraVet reports its 2022 half-year results and provides an update on the development of its activities


1 July 2022



TheraVet provides its 2022 first half-year operational update


30 June 2022




TheraVet annonces the commercial launch of its BIOCERA-VET product line in the United States of America




30 May 2022




TheraVet signs a distribution agreement with Nuzoa, a leading Spanish company in the distribution of veterinary products and services




English - Français - Dutch




10 May 2022




TheraVet signs an important distribution agreement with the orthopaedics & surgical instrumentation distributor, Veterinary Instrumentation



English - Français - Dutch




15 March 2022



Commercial launch of BIOCERA-VET® in United Kingdom and Ireland




English Français - Dutch



07 February 2022




TheraVet broadens its bone substitutes portfolio with an innovative line of biological bone grafts




04  February  2022




Positive results of BIOCERA-VET®-Bone Surgery presented at the Annual Conference of the US Veterinary Orthopedic Society and confirmed on a larger patients cohort



English - Français - Dutch




18 January 2022



TheraVet strengthens its sales organisation in France by signing an important distribution agreement for BIOCERA-VET®



English - Français - Dutch




16 December 2021




TheraVet is strengthening its corporate governance with the appointment of three new independent board members



English - Français - Dutch




09 December 2021




Commercial launch of BIOCERA-VET® for canine osteosarcoma in Belgium, France and The Netherlands


English - Français - Dutch




22 November 2021




TheraVet broadens significantly its BIOCERA-VET® product line through major distribution and research agreements




English - Français - Dutch




15 November 2021



TheraVet announces positive safety and efficacy results for BIOCERA-VET® in canine osteosarcoma



26 October 2021




First patients treated with BIOCERA-VET® Bone Surgery in the United States of America




21 October 2021



Commercial Launch of BIOCERA-VET® in France and The Netherlands




English - Français - Dutch




02 July 2021




TheraVet extends the use of BIOCERA-VET® to new curative approach of osteosarcoma in dogs




English - Français - Dutch




27 April 2021




BIOCERA-VET®: a promising alternative to autologous bone graft in canine arthrodesis




English - Français - Dutch




01 April 2021




TheraVet announces the commercial launch of BIOCERA-VET®




17 November 2020




TheraVet launches a prospective multicentric clinical trial in canine osteosarcoma




English - Français




For more press releases, click here
This website uses cookies The website of TheraVet SA uses functional cookies. In case of analysing our traffic or advertising, we also place cookies that share information about your use of our site with our analytics partners, our social media and advertising partners, who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
Show details Hide details
Allow selection Allow all cookies